Over 1,000 Chemotherapy Protocols And Counting

Phase II-III, multicenter, randomized, double-blind, placebo-controlled study (SEAL) Advanced dedifferentiated liposarcoma who received 2-5 lines chemotherapy Selinexor (N: 188) or

23 Sep

Diffuse Large B Cell Lymphoma

New Drug: Glofitamab for Large B Cell Lymphoma

Phase 2 study Relapsed or refractory DLBCL, transformed follicular lymphoma, high-grade B-cell lymphoma, or primary mediastinal large B-cell lymphoma Obinituzumab and Glofitamab (n

23 Sep

Multiple Myeloma

New Drug: Talquetamab for Multiple Myeloma

Multicenter, open-label, single-arm trial Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibit

23 Sep

Chronic Lymphocytic Leukemia

New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL

Phase II, open label, multicenter (CLL-2-Give) Previously untreated patients with high-risk chronic lymphocytic leukemia (CLL) with del(17p) and/or TP53 mutation GIVe (Venetoclax +

23 Sep

Multiple Myeloma

New Indication: Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone for Untreated High-Risk Multiple Myeloma

Phase II, non-randomised, multicenter (GMMG-CONCEPT) Newly diagnosed multiple myeloma (NDMM) with exclusively high-risk disease Arm A: Isa-KRd followed by ASCT followed İsa-KRd (T

23 Sep

Follicular Lymphoma

New Indication: Zanubrutinib and Obinutuzumab for R/R Follicular Lymphoma

Phase II, randomised (ROSEWOOD) Relapsed/refractory (R/R) follicular lymphoma (FL), who had ≥2 lines therapy Zanubritinib +Obinutuzumab (n=145) vs. Obinutuzumab (n=72)

23 Sep

Uterine Cancer

New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer

Phase III, randomised, prospective, multicenter double-blind, placebo-controlled study (ENGOT-EN5/GOG-3055/SIENDO) Patients 18 years or older with histologically confirmed EC, who

23 Sep

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC

Multicenter, blinded, phase 2 study Previously treated (platinum-containing therapy) patients with HER2m mNSCLC Trastuzumab deruxtecan: 5.4 mg/kg (n=102) vs. 6.4 mg/kg (n=52)

23 Sep

Biliary Tract Cancer

New Reference: Erdafitinib for Advanced Solid Tumors with FGFR Alterations

Phase II, single-arm, multicohort (RAGNAR) Patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries